We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » U.S. FDA to Reveal Biosimilars Naming Policy Later This Year
U.S. FDA to Reveal Biosimilars Naming Policy Later This Year
The U.S. Food and Drug Administration plans to provide guidance by year’s end on naming biosimilars, potentially ending much of the confusion over how the products will be labeled and tracked.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor